Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.

@article{BerryKravis2012EffectsOS,
  title={Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.},
  author={Elizabeth M. Berry-Kravis and David Hessl and Barbara Rathmell and Peter Zarevics and Maryann Cherubini and Karen L Walton-Bowen and Yi Mu and Danh V. Nguyen and Joseph Gonzalez-Heydrich and Paul P. Wang and Randall L. Carpenter and Mark F. Bear and Randi J. Hagerman},
  journal={Science translational medicine},
  year={2012},
  volume={4 152},
  pages={152ra127}
}
Research on animal models of fragile X syndrome suggests that STX209, a γ-aminobutyric acid type B (GABA(B)) agonist, might improve neurobehavioral function in affected patients. We evaluated whether STX209 improves behavioral symptoms of fragile X syndrome in a randomized, double-blind, placebo-controlled crossover study in 63 subjects (55 male), ages 6 to 39 years, with a full mutation in the FMR1 gene (>200 CGG triplet repeats). We found no difference from placebo on the primary endpoint… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS